February 4, 2025

Cumberland Pharmaceuticals Announces Positive Results from Phase 2 FIGHT DMD Trial of Ifetroban for Treatment of Duchenne Cardiomyopathy

Cumberland Pharmaceuticals Inc. has announced positive top-line results from its Phase 2 FIGHT DMD trial evaluating ifetroban for the treatment of Duchenne cardiomyopathy. Ifetroban is an oral thromboxane receptor antagonist aimed at reducing inflammation and…

Learn More

January 27, 2025

Sarepta Therapeutics Announces Results from Part 2 of EMBARK Study of ELEVIDYS

Sarepta Therapeutics, Inc. has announced positive topline results from Part 2 of EMBARK, the company’s Phase 3 clinical study of ELEVIDYS. ELEVIDYS is a micro-dystrophin gene therapy used for the treatment of individuals aged four…

Learn More

January 23, 2025

Update from PPMD’s 2025 Duchenne Healthcare Professionals Summit

PPMD recently convened over 360 healthcare professionals, researchers, and industry partners, including representatives from the FDA, NIH, CDC, and international representatives in one room to discuss the latest updates in dystrophinopathy care and research at…

Learn More

January 17, 2025

Race to End Duchenne Kicks Off 20th Anniversary at Walt Disney World Marathon Weekend

The Race to End Duchenne program is celebrating our 20th anniversary in 2025, and we spent the weekend of January 8-12 kicking it off at the place where it all began – the Walt Disney…

Learn More

January 16, 2025

PPMD Advocacy in the 119th Congress and the 47th Administration

As the 119th Congress and the 47th Administration prepare to take office, PPMD is committed to furthering the needs of our community through comprehensive, creative, and tenacious advocacy on Capitol Hill, regardless of politics. Over…

Learn More

January 16, 2025

Advance the Research Evolution with The Duchenne Registry

Everyone can help advance the research evolution for Duchenne and Becker. Bringing data sources together from multiple research endeavors is a key component of PPMD’s plan to advance the research evolution, and The Duchenne Registry…

Learn More

January 15, 2025

PPMD Hosts 2025 Duchenne Healthcare Professionals Summit in San Diego, California

PPMD is excited to host the sixth in-person Duchenne Healthcare Professionals Summit in San Diego, California, January 15-17. Since the Summit’s inception in 2018, the event has brought together thousands of healthcare providers, researchers, leaders…

Learn More

January 10, 2025

Introducing PPMD’s Dystrophinopathy Clinical Research Network (DCRN): Advancing the Research Evolution

In our rapidly evolving therapeutic landscape, there is a critical need for cohesive infrastructure that helps track what happens when individuals are on more than one therapy and how we can continue to evolve standards…

Learn More

January 9, 2025

Avidity Biosciences Announces Plans to File Biologics License Application for Delpacibart Zotadirsen (AOC 1044)

Avidity Biosciences, Inc. has announced its plans for filing a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for delpacibart zotadirsen (del-zota) for treatment of individuals living with Duchenne muscular dystrophy…

Learn More

January 8, 2025

PPMD’s Race to End Duchenne Program Celebrates 20 Years of Going the Distance to End Duchenne

PPMD is celebrating the 20th anniversary of our endurance fundraising program, Race to End Duchenne, this weekend in Orlando, Florida. 185 team members will participate in the 2025 Walt Disney World® Marathon Weekend, presented by…

Learn More